{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Solara Active Pharma Sciences Ltd Falls to 52-Week Low of Rs.426.15
Solara Active Pharma Sciences Ltd’s share price declined to a fresh 52-week low of Rs.426.15 today, marking a significant milestone in the stock’s recent downward trajectory amid broader market pressures and company-specific performance concerns.
Solara Active Pharma Sciences Ltd Falls to 52-Week Low of Rs.440
Solara Active Pharma Sciences Ltd has touched a new 52-week low of Rs.440 today, marking a significant decline in its stock price amid broader market weakness and company-specific concerns. The stock has underperformed its sector and key benchmarks, reflecting ongoing challenges in its financial and market performance.
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Solara Active Pharma Sciences Ltd Falls to 52-Week Low of Rs.440.4
Solara Active Pharma Sciences Ltd’s stock declined to a fresh 52-week low of Rs.440.4 on 2 Mar 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial and market performance.
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Solara Active Pharma Gains 6.03%: Key Financial and Market Developments This Week
Solara Active Pharma Sciences Ltd delivered a notable weekly gain of 6.03%, closing at Rs.499.60 on 13 Feb 2026, outperforming the Sensex which declined by 0.54% over the same period. The stock showed resilience despite early-week pressures, including a fresh 52-week low and flat quarterly results, before rallying strongly on the final trading day amid broader market weakness.
Solara Active Pharma Sciences Ltd Falls to 52-Week Low of Rs.441
Solara Active Pharma Sciences Ltd has reached a new 52-week low, closing at Rs.441 today, marking a significant decline amid a broader market that continues to show resilience. The stock’s recent performance reflects ongoing concerns within the Pharmaceuticals & Biotechnology sector, with the share price underperforming both its peers and the benchmark indices.
Solara Active Pharma Sciences Ltd Reports Flat Quarterly Performance Amid Margin Pressures
Solara Active Pharma Sciences Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a pause in its recent downward trend. Despite achieving its highest quarterly net sales to date, the company continues to grapple with margin contraction and net losses, prompting a cautious outlook from analysts.
Are Solara Active Pharma Sciences Ltd latest results good or bad?
Solara Active Pharma Sciences Ltd's latest Q3 FY26 results are concerning, showing a net loss of ₹17.43 crores despite an 11.31% increase in net sales. The company faces significant operational challenges, with declining margins and a weak liquidity position, indicating a disconnect between revenue growth and profitability.
Solara Active Pharma Falls 6.67%: Margin Pressures and Volatility Weigh on Shares
Solara Active Pharma Sciences Ltd experienced a turbulent week ending 6 February 2026, with its share price declining 6.67% to close at Rs.471.20, sharply underperforming the Sensex which gained 1.51% over the same period. Despite early gains in the week, the stock faced mounting selling pressure amid disappointing quarterly results and heightened intraday volatility, culminating in a steep drop on the final trading day.
Why is Solara Active Pharma Sciences Ltd falling/rising?
On 06-Feb, Solara Active Pharma Sciences Ltd witnessed a sharp decline in its share price, falling 10.1% to close at ₹471.20. This drop reflects a continuation of recent negative trends driven by weak financial performance, deteriorating investor confidence, and underwhelming market returns relative to benchmarks.
Are Solara Active Pharma Sciences Ltd latest results good or bad?
Solara Active Pharma Sciences Ltd's latest results show a net profit of ₹10.52 crores, a recovery from a previous loss, but a year-on-year revenue decline of 12.20% indicates ongoing challenges. Overall, while there are signs of improvement, the company faces significant risks due to low return ratios and a volatile shareholding pattern.
Solara Active Pharma Q3 FY26: Margin Compression Triggers Sharp Loss Despite Revenue Growth
Solara Active Pharma Sciences Ltd., a small-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients (APIs), reported a disappointing Q3 FY26 performance marked by severe margin compression that overshadowed revenue growth. The company posted a net loss of ₹17.43 crores for the quarter ended December 2025, a sharp deterioration from the ₹10.52 crores profit recorded in Q2 FY26 and significantly worse than the ₹8.09 crores profit in Q3 FY25. The stock plummeted 10.10% to ₹471.20 following the results, reflecting investor concerns about the company's profitability trajectory despite a ₹1,897 crore market capitalisation.
Solara Active Pharma Sciences Ltd Hits Intraday Low Amid Price Pressure
Solara Active Pharma Sciences Ltd experienced a significant intraday decline on 6 Feb 2026, touching a low of Rs 482.2, down 8.06% from the previous close. The stock underperformed its sector and broader market indices, reflecting immediate selling pressure and heightened volatility.
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 January 2026, providing investors with the latest comprehensive view.
Solara Active Pharma Sciences Ltd is Rated Strong Sell
Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
